Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Billions in market cap are being shed as the markets reel over President Donald Trump’s escalating trade war. Eli Lilly’s ...

A consumer-driven weight loss market could put pharma at greater risk if a recession hits; the continued turmoil at FDA and other HHS agencies magnifies the uncertainty facing the industry; Lilly ...

Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as ...

The Trump administration reversed a Biden-era proposal for Medicare coverage of anti-obesity treatments. But on Monday, HHS ...

Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing ...

The company is dropping its former lead molecule in favor of another antibody, RLYB116, which is being developed for a ...

Senators Bill Cassidy and Bernie Sanders asked HHS Secretary Robert F. Kennedy, Jr. to make good on a pledge to appear before ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

Senators Bill Cassidy and Bernie Sanders asked HHS Secretary Robert F. Kennedy, Jr., to make good on a pledge to appear ...

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.